Why GNBT/NGIO has an Advantage in the Covid-19 Vac
Post# of 36568
(Total Views: 866)
Posted On: 03/29/2020 12:04:21 PM
Why GNBT/NGIO has an Advantage in the Covid-19 Vaccine Race
NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The
focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone.
Rapid Path to SARS-COV-2 Vaccine: 3 Months to Human Vaccination
NuGenerex Immuno-Oncology, a Subsidiary of Generex Biotechnology (NGIO) has developed our proprietary, patented Ii-Key immune system
activation technology that holds promise for stopping pandemic viral outbreaks like the current SARS-COV-2 coronavirus epidemic in China. NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The
focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone. The activity and safety of Ii Key peptide vaccines has been proven in Phase I and II clinical trials involving over 300 patients or volunteers, so new Ii-Key has been proven in Phase I
and II clinical trials involving over 300 patients or volunteers, so new Ii-Key vaccines should be able to proceed directly to human studies without significant pre-clinical toxicology testing. With human clinical data in hundreds of patients that demonstrate safety and immune system activation against infectious disease and tumor antigens, as well as preclinical in vitro and in vivo studies that prove the mechanism of T-Cell activation, the Ii-Key technology offers a rapid path to humanprotection from the SARS-COV-2 and COVID-19 epidemic.
NGIO is working with EpiVax to utilize their proprietary computational vaccinology algorithms and databases to guide the rapid development of Ii-Key peptide vaccines to protect against the spread of SARS-COV-2. EpiVax has developed a suite of online computational vaccinology tools
for the accelerated design of proteome-derived, epitope-driven vaccines. NGIO and EpiVax are generating new patents and intellectual
properties from this collaborative agreement.
NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The
focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone.
Rapid Path to SARS-COV-2 Vaccine: 3 Months to Human Vaccination
NuGenerex Immuno-Oncology, a Subsidiary of Generex Biotechnology (NGIO) has developed our proprietary, patented Ii-Key immune system
activation technology that holds promise for stopping pandemic viral outbreaks like the current SARS-COV-2 coronavirus epidemic in China. NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The
focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone. The activity and safety of Ii Key peptide vaccines has been proven in Phase I and II clinical trials involving over 300 patients or volunteers, so new Ii-Key has been proven in Phase I
and II clinical trials involving over 300 patients or volunteers, so new Ii-Key vaccines should be able to proceed directly to human studies without significant pre-clinical toxicology testing. With human clinical data in hundreds of patients that demonstrate safety and immune system activation against infectious disease and tumor antigens, as well as preclinical in vitro and in vivo studies that prove the mechanism of T-Cell activation, the Ii-Key technology offers a rapid path to humanprotection from the SARS-COV-2 and COVID-19 epidemic.
NGIO is working with EpiVax to utilize their proprietary computational vaccinology algorithms and databases to guide the rapid development of Ii-Key peptide vaccines to protect against the spread of SARS-COV-2. EpiVax has developed a suite of online computational vaccinology tools
for the accelerated design of proteome-derived, epitope-driven vaccines. NGIO and EpiVax are generating new patents and intellectual
properties from this collaborative agreement.
(0)
(0)